Validity and reliability of the QLQ-MY20 module for assessing the health-related quality of life in Brazilians with multiple myeloma

References

• Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
   PubMed Web of Science ®Google Scholar
• Durie BGM. Mieloma Multiplo: Revisão Concisa da Doença e Opções de Tratamento [Internet]. São Paulo (Brazil): International Myeloma Foundation; 2017 [cited 2019 Dec 12]. Available from: https://www.myeloma.org.br/publicacoes.php
   Google Scholar
• Brasil. Estimativa 2018: incidência de câncer no Brasil. Rio de Janeiro (Brazil): INCA; 2017.
   Google Scholar
• WHO. Global cancer observatory [Internet]. Paris (France): WHO; 2019 [cited 2019 Feb 2]. Available from: http://gco.iarc.fr/
   Google Scholar
• Cowan AJ, Allen C, Barac A, et al. Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018;4(9):1221–1227.
   PubMed Web of Science ®Google Scholar
• IHME. Global burden of disease - GBD compare [Internet]. Seattle (WA): Institute for Health Metrics and Evaluation; 2017 [cited 2020 Feb 2]. Available from: https://vizhub.healthdata.org/gbd-compare/
   Google Scholar
• Kazandjian D, Landgren O. A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival. Semin Oncol. 2016;43(6):682–689.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–1128.
   PubMed Web of Science ®Google Scholar
• Ramsenthaler C, Osborne TR, Gao W, et al. The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. BMC Cancer. 2016;16(1):427.
   PubMed Web of Science ®Google Scholar
• Zanwar S, Abeykoon JP, Kapoor P. Challenges and strategies in the management of multiple myeloma in the elderly population. Curr Hematol Malig Rep. 2019;14(2):70–82.
   PubMed Web of Science ®Google Scholar
• Barth P, Vale C, Chambers AB, et al. The next generation of therapy for multiple myeloma: a review of ongoing clinical trials utilizing ClinicalTrials.gov. Future Oncol. 2018;14(19):1965–1976.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Dimopoulos MA, Masszi T, et al. Health-related quality-of-life results from the Open-Label, Randomized, Phase III ASPIRE Trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol. 2016;34(32):3921–3930.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Moreau P, Dimopoulos MA, et al. Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J. 2019;9(3):23.
   PubMed Web of Science ®Google Scholar
• Grant SR, Noticewala SS, Mainwaring W, et al. Non-English language validation of patient-reported outcome measures in cancer clinical trials. Support Care Cancer. 2020;28(6):2503–2505.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376.
   PubMed Web of Science ®Google Scholar
• Cocks K, Cohen D, Wisløff F, et al. An international field study of the reliability and validity of a disease- specific questionnaire module (the QLQ- MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer. 2007;43(11):1670–1678.
   PubMed Web of Science ®Google Scholar
• EORTC. EORTC quality of life Belgium [Internet]. Brussels (Belgium): EORTC; 2019 [cited 2019 Feb 2]. Available from: https://qol.eortc.org/modules/
   Google Scholar
• Johnson C, Aaronson N, Blazeby JM, et al. Guidelines for developing questionnaire modules [Internet]. Brussels (Belgium): EORTC; 2011 [cited 2020 Feb 12]. Available from: https://www.eortc.org/app/uploads/sites/2/2018/02/guidelines_for_developing_questionnaire-_final.pdf
   Google Scholar
• Kuliś D, Bottomley A, Velikova G, et al. EORTC quality of life group translation procedure. Brussels (Belgium): EORTC; 2017.
   Google Scholar
• Kontodimopoulos N, Samartzis A, Papadopoulos AA, et al. Reliability and validity of the Greek QLQ-C30 and QLQ-MY20 for measuring quality of life in patients with multiple myeloma. Sci World J. 2012;2012(842867):1–8.
   Web of Science ®Google Scholar
• Espinoza-Zamora J, Portilla-Espinosa C, Labardini-Méndez J, et al. Quality of life in multiple myeloma: clinical validation of the Mexican-Spanish version of the QLQ-MY20 instrument. Ann Hematol. 2015;94(6):1017–1024.
   PubMed Web of Science ®Google Scholar
• Graça Pereira M, Ferreira G, Pereira M, et al. Validation of the Quality of Life Multiple Myeloma Module Questionnaire (QLQ-MY20) in Portuguese myeloma patients. Eur J Cancer Care. 2019;28(5):e13128.
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh A, Yekaninejad MS, Saffari M, et al. Reliability and validity of an Iranian version of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with multiple myeloma: the EORTC QLQ-MY20. Asian Pac J Cancer Prev. 2016;17(1):255–259.
   PubMedGoogle Scholar
• EORTC. EORTC QLQ-C30 scoring manual Belgium: EORTC quality of life group [Internet]. Brussels (Belgium): EORTC; 2001 [cited 2019 Dec 17]; Available from: https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf
   Google Scholar
• Paiva C, Carneseca E, Barroso E, et al. Further evaluation of the EORTC QLQ-C30 psychometric properties in a large Brazilian cancer patient cohort as a function of their educational status. Support Care Cancer. 2014;22(8):2151–2160.
   PubMed Web of Science ®Google Scholar
• Etto LY, Morelli VM, Silva VC, et al. Autologous stem cell transplantation improves quality of life in economically challenged, Brazilian multiple myeloma patients. Clinics. 2011;66(11):1855–1859.
   PubMed Web of Science ®Google Scholar
• EORTC. EORTC QLQ-MY20 scoring manual [Internet]. Brussels (Belgium): EORTC; 2007 [cited 2020 Feb 22]. Available from: https://qol.eortc.org/manuals/.
   Google Scholar
• Nunes BP, Batista SRR, Andrade FBd, et al. Multimorbidity: the Brazilian longitudinal study of aging (ELSI-Brazil). Rev Saúde Pública. 2019;52(2):10s.
   Web of Science ®Google Scholar
• Pasquali L. Psicometria: teoria dos testes na psicologia e na educação. 1st ed. Vol. 1. Petrópolis (Brazil): Editora Vozes; 2011.
   Google Scholar
• Streiner DL. Being inconsistent about consistency: when coefficient alpha does and doesn’t matter. J Pers Assess. 2003;80(3):217–222.
   PubMed Web of Science ®Google Scholar
• Prinsen CAC, Mokkink LB, Bouter LM, et al. COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual Life Res. 2018;27(5):1147–1157.
   PubMed Web of Science ®Google Scholar
• Tavakol M, Dennick R. Making sense of Cronbach’s alpha. Int J Med Educ. 2011;2:53.
   PubMedGoogle Scholar
• de Vet H, Terwee C, Mokkink L, et al. Measurement in medicine - a practical guide. New York (NY): Cambridge University Press; 2011.
   Google Scholar
• Dmitrienko A, Chuang-Stein C, D’Agostino R. Pharmaceutical statistics using SAS: a practical guide. Cary (NC): SAS; 2007.
   Google Scholar
• Gordia AP, Quadros TMB, Oliveira MTC, et al. Qualidade de vida: contexto histórico, definição, avaliação e fatores associados. Rev Bras Qual Vida. 2011;3(1):40–52.
   Google Scholar
• Curado MP, Oliveira MM, Silva DRM, et al. Epidemiology of multiple myeloma in 17 Latin American countries: an update. Cancer Med. 2018;7(5):2101–2108.
   PubMed Web of Science ®Google Scholar
• Hungria VTM, Chiattone C, Pavlovsky M, et al. Epidemiology of hematologic malignancies in real-world settings: findings from the Hemato-Oncology Latin America Observational Registry Study. J Glob Oncol. 2019;5:1–19.
   Web of Science ®Google Scholar